ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van Aken Evert S M, Gandhi Ajeet Kumar, O'Cathail Sean M, Borst Gerben, Barriuso Jorge, Fokas Emmanouil, Castelo-Branco Luis, Ree Anne Hansen, de Azambuja Evandro, Kroeze Stephanie, Colombo Ilaria, Levy Antonin, Criscitiello Carmen, Niyazi Maximilian, Harbeck Nadia, Szutowicz Ewa, Liposits Gabor, Verheij Marcel, Ray-Coquard Isabelle, Tarantino Paolo, Trapani Dario, Boot Paulien, Belka Claus, Ruysscher Dirk De, Pentheroudakis George, Marijnen Corrie A M, Lordick Florian, Ricardi Umberto, Martins-Branco Diogo, Prelaj Arsela, de Jong Monique C, Devnani Bharti
Аннотация
DESIGN: The European Society for Medical Oncology (ESMO) and the European SocieTy for Radiotherapy and Oncology (ESTRO) developed a series of systematic reviews with multidisciplinary, tumor-agnostic, evidence-based Delphi consensus statements regarding the safety of combining RT with targeted agents or immunotherapy. The current study addresses the safety of combining RT with CDK4/6 inhibitors, anti-HER2 monoclonal antibodies, PARP inhibitors, or mTOR-inhibitors. During the modified Delphi process, two digital voting rounds were organized with 18 international experts. By systematically evaluating the different drug classes and irradiated areas, 74 clinical scenarios were assessed. Safety statements were formulated for all scenarios, based on the evidence from the systematic literature reviews.
RESULTS: A total of 1,341 records were screened during the systematic literature reviews, of which 107 studies were ultimately included in the final reviews and the literature database. After two Delphi voting rounds, agreement was reached on all 74 scenario-specific safety statements.
CONCLUSIONS: The expected combined toxicity is often low for anti-HER2 monoclonal antibodies. For most scenarios with CDK4/6, PARP, or mTOR inhibitors, exercising caution is recommended.